{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:56:58Z","timestamp":1781031418965,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000142","name":"Arthritis Society","doi-asserted-by":"publisher","award":["SOG18-0253"],"award-info":[{"award-number":["SOG18-0253"]}],"id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00823-4","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:59:12Z","timestamp":1781027952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Responsiveness of the EQ-5D-Y-5L Parent-Proxy Version Among Children with Juvenile Idiopathic Arthritis"],"prefix":"10.1007","author":[{"given":"Deborah A.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-9893","authenticated-orcid":false,"given":"Gillian R.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost F.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae S. M.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto","family":"Ohinmaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"1","key":"823_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00332-8","volume":"8","author":"A Martini","year":"2022","unstructured":"Martini A, Lovell DJ, Albani S, Brunner HI, Hyrich KL, Thompson SD, et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8(1):1\u201318. https:\/\/doi.org\/10.1038\/s41572-021-00332-8.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"823_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra2402073","volume":"393","author":"CI Sandborg","year":"2025","unstructured":"Sandborg CI, Schulert GS, Kimura Y. Juvenile idiopathic arthritis. N Engl J Med. 2025;393(2):162\u201374. https:\/\/doi.org\/10.1056\/NEJMra2402073.","journal-title":"N Engl J Med"},{"issue":"2","key":"823_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Jt Bone Spine. 2014;81(2):112\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2013.09.003.","journal-title":"Jt Bone Spine"},{"key":"823_CR4","unstructured":"Public Health Agency of Canada. (2020, September 29). Juvenile idiopathic arthritis in Canada. research. Retrieved 20 January 2023 from https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/juvenile-idiopathic-arthritis.html"},{"issue":"1","key":"823_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13075-019-1950-7","volume":"21","author":"G Giancane","year":"2019","unstructured":"Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, et al. Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168. https:\/\/doi.org\/10.1186\/s13075-019-1950-7.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"823_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00641-y","volume":"19","author":"F Garc\u00eda-Rodr\u00edguez","year":"2021","unstructured":"Garc\u00eda-Rodr\u00edguez F, Gamboa-Alonso A, Jim\u00e9nez-Hern\u00e1ndez S, Ochoa-Alderete L, Barrientos-Mart\u00ednez VA, Alvarez-Villalobos NA, et al. Economic impact of juvenile idiopathic arthritis: A systematic review. Pediatr Rheumatol. 2021;19(1):152. https:\/\/doi.org\/10.1186\/s12969-021-00641-y.","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"823_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.36469\/001c.85088","volume":"10","author":"J Ant\u00f3n","year":"2023","unstructured":"Ant\u00f3n J, Moreno Ruzafa E, Lopez Corbeto M, Bou R, S\u00e1nchez Manubens J, Carriqu\u00ed Arenas S, et al. Real-world health care outcomes and costs among patients with juvenile idiopathic arthritis in Spain. J Health Econ Outcomes Res. 2023;10(2):141\u20139. https:\/\/doi.org\/10.36469\/001c.85088.","journal-title":"J Health Econ Outcomes Res"},{"issue":"SI2","key":"823_CR8","doi-asserted-by":"publisher","first-page":"SI143","DOI":"10.1093\/rheumatology\/kead688","volume":"63","author":"AA Florax","year":"2024","unstructured":"Florax AA, Doeleman MJH, de Roock S, van der Linden N, Schatorj\u00e9 E, Currie G, et al. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-\u03b1 inhibitors in juvenile idiopathic arthritis. Rheumatology Oxford. 2024;63(SI2):SI143\u201351. https:\/\/doi.org\/10.1093\/rheumatology\/kead688. (for UCAN-CAN DU and UCAN CURE Consortia).","journal-title":"Rheumatology Oxford"},{"issue":"1","key":"823_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00713-7","volume":"20","author":"LR Grazziotin","year":"2022","unstructured":"Grazziotin LR, Currie G, Twilt M, IJzerman MJ, Kip MMA, Koffijberg H, et al. Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2022;20(1):51. https:\/\/doi.org\/10.1186\/s12969-022-00713-7.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"823_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/acr.24621","volume":"74","author":"MMA Kip","year":"2022","unstructured":"Kip MMA, de Roock S, van den Berg I, Currie G, Marshall DA, Grazziotin LR, et al. Costs of hospital-associated care for patients with juvenile idiopathic arthritis in the Dutch health care system. Arthritis Care Res Hoboken. 2022;74(10):1585\u201392. https:\/\/doi.org\/10.1002\/acr.24621.","journal-title":"Arthritis Care Res Hoboken"},{"issue":"12","key":"823_CR11","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761\u20139. https:\/\/doi.org\/10.1002\/art.1780371209.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"823_CR12","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11136-019-02115-x","volume":"28","author":"S Kreimeier","year":"2019","unstructured":"Kreimeier S, \u00c5str\u00f6m M, Burstr\u00f6m K, Egmar A-C, Gusi N, Herdman M, et al. EQ-5D-Y-5L: Developing a revised EQ-5D-Y with increased response categories. Qual Life Res. 2019;28(7):1951\u201361. https:\/\/doi.org\/10.1007\/s11136-019-02115-x.","journal-title":"Qual Life Res"},{"issue":"6","key":"823_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","volume":"19","author":"N Wille","year":"2010","unstructured":"Wille N, Badia X, Bonsel G, Burstr\u00f6m K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: A child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875\u201386. https:\/\/doi.org\/10.1007\/s11136-010-9648-y.","journal-title":"Qual Life Res"},{"issue":"10","key":"823_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"1","key":"823_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-022-01938-6","volume":"20","author":"J Verstraete","year":"2022","unstructured":"Verstraete J, Marthinus Z, Dix-Peek S, Scott D. Measurement properties and responsiveness of the EQ-5D-Y-5L compared to the EQ-5D-Y-3L in children and adolescents receiving acute orthopaedic care. Health Qual Life Outcomes. 2022;20(1):1\u201314. https:\/\/doi.org\/10.1186\/s12955-022-01938-6.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"823_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10198-022-01435-z","volume":"23","author":"J Lin","year":"2022","unstructured":"Lin J, Wong CKH, Cheung JPY, Cheung PWH, Luo N. Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis. Eur J Health Econ. 2022;23(8):1383\u201395. https:\/\/doi.org\/10.1007\/s10198-022-01435-z.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"823_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-021-01889-4","volume":"19","author":"TS Fitriana","year":"2021","unstructured":"Fitriana TS, Purba FD, Rahmatika R, Muhaimin R, Sari NM, Bonsel G, et al. Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients. Health Qual Life Outcomes. 2021;19(1):1\u201312. https:\/\/doi.org\/10.1186\/s12955-021-01889-4.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"823_CR18","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00431-022-04626-1","volume":"181","author":"RH Xu","year":"2022","unstructured":"Xu RH, Zhu L, Sun R, Tan RL-Y, Luo N, Zou S, et al. Investigating the psychometric properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL in children and adolescents with osteogenesis imperfecta. Eur J Pediatr. 2022;181(12):4049\u201358. https:\/\/doi.org\/10.1007\/s00431-022-04626-1.","journal-title":"Eur J Pediatr"},{"issue":"18","key":"823_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191811420","volume":"19","author":"MA Perez-Sousa","year":"2022","unstructured":"Perez-Sousa MA, Olivares PR, Gusi N. Psychometric properties of the Spanish versions of EQ-5D-Y-3L and EQ-5D-Y-5L in children with cancer: a comparative study. Int J Environ Res Public Health. 2022;19(18):11420. https:\/\/doi.org\/10.3390\/ijerph191811420.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"823_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10198-021-01309-w","volume":"22","author":"W Zhou","year":"2021","unstructured":"Zhou W, Shen A, Yang Z, Wang P, Wu B, Herdman M, et al. Patient-caregiver agreement and test\u2013retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies. Eur J Health Econ. 2021;22(7):1103\u201313. https:\/\/doi.org\/10.1007\/s10198-021-01309-w.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"823_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-022-01996-w","volume":"20","author":"TS Fitriana","year":"2022","unstructured":"Fitriana TS, Purba FD, Stolk E, Busschbach JJV. EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report. Health Qual Life Outcomes. 2022;20(1):1\u201313. https:\/\/doi.org\/10.1186\/s12955-022-01996-w.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"823_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s41687-022-00480-9","volume":"6","author":"J Verstraete","year":"2022","unstructured":"Verstraete J, Scott D. Comparison of the EQ-5D-Y-5L, EQ-5D-Y-3L and PedsQL in children and adolescents. J Patient Rep Outcomes. 2022;6(1):67. https:\/\/doi.org\/10.1186\/s41687-022-00480-9.","journal-title":"J Patient Rep Outcomes"},{"issue":"10","key":"823_CR23","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s11136-024-03682-4","volume":"33","author":"A Ohinmaa","year":"2024","unstructured":"Ohinmaa A, Wen J, Currie GR, Benseler SM, Swart JF, Vastert SJ, et al. Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis. Qual Life Res. 2024;33(10):2677\u201391. https:\/\/doi.org\/10.1007\/s11136-024-03682-4.","journal-title":"Qual Life Res"},{"key":"823_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-025-00953-0","author":"C de Melo do Espirito Santo","year":"2025","unstructured":"de Melo do Espirito Santo C, Santos VS, Chiarotto A, Miyamoto GC, Yamato TP. Measurement properties of the EQ-5D instruments in children and adolescents: a systematic review. Appl Health Econ Health Policy. 2025. https:\/\/doi.org\/10.1007\/s40258-025-00953-0.","journal-title":"Appl Health Econ Health Policy"},{"key":"823_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.03.020","author":"LJ Cheng","year":"2025","unstructured":"Cheng LJ, Schieskow S, Chen LA, Cheng JY, Herdman M, Luo N. Head-to-head comparisons of the distributional characteristics and measurement properties of the 3-level and 5-level versions of the EQ-5D-Y: a systematic review. Value Health. 2025. https:\/\/doi.org\/10.1016\/j.jval.2025.03.020.","journal-title":"Value Health"},{"issue":"11","key":"823_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/acr.22393","volume":"66","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Negro G, Chiara Gallo M, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res Hoboken. 2014;66(11):1703\u20139. https:\/\/doi.org\/10.1002\/acr.22393.","journal-title":"Arthritis Care Res Hoboken"},{"issue":"S5","key":"823_CR27","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/art.11398","volume":"49","author":"SE Klepper","year":"2003","unstructured":"Klepper SE. Measures of pediatric function: the Child Health Assessment Questionnaire (CHAQ), Juvenile Arthritis Functional Assessment Report (JAFAR), Juvenile Arthritis Functional Assessment Scale (JAFAS), Juvenile Arthritis Functional Status Index (JASI), and Pediatric Orthopedic Surgeons of North America (POSNA) pediatric musculoskeletal functional health questionnaire. Arthritis Care Res Hoboken. 2003;49(S5):S5\u201314.","journal-title":"Arthritis Care Res Hoboken"},{"issue":"11","key":"823_CR28","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C","volume":"43","author":"LR Spiegel","year":"2000","unstructured":"Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000;43(11):2402\u20139. https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11%3c2402::AID-ANR5%3e3.0.CO;2-C.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"823_CR29","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.41879","volume":"73","author":"C Trincianti","year":"2021","unstructured":"Trincianti C, Van Dijkhuizen EHP, Alongi A, Mazzoni M, Swart JF, Nikishina I, et al. Definition and validation of the American College of Rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(11):1966\u201375. https:\/\/doi.org\/10.1002\/art.41879.","journal-title":"Arthritis Rheumatol"},{"key":"823_CR30","unstructured":"EuroQol Research Foundation. (2024). EQ-5D-Y-5L user guide. Retrieved from https:\/\/euroqol.org\/information-and-support\/documentation\/user-guides\/"},{"issue":"5","key":"823_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40271-021-00496-1","volume":"14","author":"S Derrett","year":"2021","unstructured":"Derrett S, Herdman M, Ngwira LG, Moore EY, Jelsma J. A new approach to assessing children\u2019s interpretation of severity qualifiers in a multi-attribute utility instrument\u2013the EQ-5D-Y-5L: development and testing. Patient. 2021;14(5):591\u2013600. https:\/\/doi.org\/10.1007\/s40271-021-00496-1.","journal-title":"Patient"},{"issue":"1","key":"823_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11136-021-02922-1","volume":"31","author":"Y-S Feng","year":"2022","unstructured":"Feng Y-S, Jiang R, Pickard AS, Kohlmann T. Combining EQ-5D-5L items into a level summary score: demonstrating feasibility using non-parametric item response theory using an international dataset. Qual Life Res. 2022;31(1):11\u201323. https:\/\/doi.org\/10.1007\/s11136-021-02922-1.","journal-title":"Qual Life Res"},{"key":"823_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-47622-9_2","volume-title":"Methods for analysing and reporting EQ-5D data","author":"N Devlin","year":"2020","unstructured":"Devlin N, Parkin D, Janssen B. Analysis of EQ-5D profiles. In: Devlin N, Parkin D, Janssen B, editors. Methods for analysing and reporting EQ-5D data. Cham: Springer International Publishing; 2020. p. 23\u201349. https:\/\/doi.org\/10.1007\/978-3-030-47622-9_2."},{"issue":"4","key":"823_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1023\/A:1023499322593","volume":"12","author":"CB Terwee","year":"2003","unstructured":"Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PMM. On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res. 2003;12(4):349\u201362. https:\/\/doi.org\/10.1023\/A:1023499322593.","journal-title":"Qual Life Res"},{"key":"823_CR35","unstructured":"Juniper, E. F., Gordon, H. G., & Roman, J. (1996). How to develop and validate a new health-related quality of life instrument. In: Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Philadelphia: Lippincott-Raven Publishers."},{"issue":"3","key":"823_CR36","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","volume":"30","author":"Y-S Feng","year":"2021","unstructured":"Feng Y-S, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021;30(3):647\u201373. https:\/\/doi.org\/10.1007\/s11136-020-02688-y.","journal-title":"Qual Life Res"},{"issue":"2","key":"823_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"823_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40273-023-01330-2","volume":"42","author":"R Jones","year":"2024","unstructured":"Jones R, O\u2019Loughlin R, Xiong X, Bahrampour M, Devlin N, Hiscock H, et al. Comparative psychometric performance of common generic paediatric health-related quality of life instrument descriptive systems: results from the Australian paediatric multi-instrument comparison study. Pharmacoeconomics. 2024;42(1):39\u201355. https:\/\/doi.org\/10.1007\/s40273-023-01330-2. (on behalf of the Quality of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team).","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"823_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40273-024-01354-2","volume":"42","author":"R O\u2019Loughlin","year":"2024","unstructured":"O\u2019Loughlin R, Jones R, Chen G, Mulhern B, Hiscock H, Devlin N, et al. Comparing the psychometric performance of generic paediatric health-related quality of life instruments in children and adolescents with ADHD, anxiety and\/or depression. Pharmacoeconomics. 2024;42(1):57\u201377. https:\/\/doi.org\/10.1007\/s40273-024-01354-2. (in collaboration with the Quality of Life in Kids: Key Evidence to Strengthen Decisions In Australia (QUOKKA) project team).","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"823_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40273-024-01350-6","volume":"42","author":"A van Heusden","year":"2024","unstructured":"van Heusden A, Rivero-Arias O, Herdman M, Hiscock H, Devlin N, Dalziel K. Psychometric performance comparison of the adapted versus original versions of the EQ-5D-Y-3L and -Y-5L in proxy respondents for 2- to 4-year-olds. Pharmacoeconomics. 2024;42(1):129\u201345. https:\/\/doi.org\/10.1007\/s40273-024-01350-6.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"823_CR41","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s10198-024-01669-z","volume":"25","author":"W Zhou","year":"2024","unstructured":"Zhou W, Shen A, Yang Z, Wang P, Wu B, Herdman M, et al. Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers. Eur J Health Econ. 2024;25(8):1361\u201370. https:\/\/doi.org\/10.1007\/s10198-024-01669-z.","journal-title":"Eur J Health Econ"},{"key":"823_CR42","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S174408","author":"DC Fair","year":"2019","unstructured":"Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: current insights and impact on quality of life, a systematic review. Open Access Rheumatol Res Rev. 2019. https:\/\/doi.org\/10.2147\/OARRR.S174408.","journal-title":"Open Access Rheumatol Res Rev"},{"issue":"4","key":"823_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153267","volume":"11","author":"S Barth","year":"2016","unstructured":"Barth S, Haas J-P, Schlichtiger J, Molz J, Bisdorff B, Michels H, et al. Long-term health-related quality of life in German patients with juvenile idiopathic arthritis in comparison to German general population. PLoS ONE. 2016;11(4):e0153267. https:\/\/doi.org\/10.1371\/journal.pone.0153267.","journal-title":"PLoS ONE"},{"issue":"8","key":"823_CR44","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/rheumatology\/key088","volume":"57","author":"L Hanns","year":"2018","unstructured":"Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the childhood arthritis prospective study. Rheumatology. 2018;57(8):1381\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/key088.","journal-title":"Rheumatology"},{"issue":"2","key":"823_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/acr.24855","volume":"75","author":"EHP van Dijkhuizen","year":"2023","unstructured":"van Dijkhuizen EHP, Ridella F, Naddei R, Trincianti C, Avrusin I, Mazzoni M, et al. Validity and reliability of four parent\/patient\u2013reported outcome measures for juvenile idiopathic arthritis remote monitoring. Arthritis Care Res. 2023;75(2):391\u2013400. https:\/\/doi.org\/10.1002\/acr.24855.","journal-title":"Arthritis Care Res"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00823-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:59:14Z","timestamp":1781027954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00823-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":45,"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00823-4","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.O. is a member of the EuroQol Group and copyright holder for the EQ-5D-5L. D.M. reports support for attending meetings from Illumina and ISPOR, and consulting fees from Office of Health Economics, Novartis, and Analytica, outside the submitted work. R.Y. reports consulting fees from AstraZeneca, Amgen, and Lily, and speaking fees\/travel reimbursement from Sobi, outside the submitted work. S.V. reports grants and personal fees from SOBI and Novartis during the conduct of the study, outside the submitted work. J.S. reports consulting fees from Amgen and Pfizer outside the submitted work. All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data are available on reasonable request, and according to the UCAN CAN-DU and UCAN CURE data-sharing policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Ethics was granted by the Conjoint Health Research Ethics Board at the University of Calgary (REB17\u20131563), the Hospital for Sick Children (Clinical Trials Ontario [CTO] no. 1771), the Health Research Ethics Board at the University of Alberta (Pro00106423), and the Ethics Board of Utrecht (18\u2013474).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"DAM, GRC, SMB, JFS, SJV, and RSMY designed the UCAN CAN-DU study cohort and led the data collection. JW conducted the analysis. AO, GRC, and DAM contributed to the interpretation. JW and AO drafted the manuscript, and all authors read, revised, and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}